ASRT assertiotx.com: Multiplikator forward rega marang pendapatan
Steady demand for amortized neuropreparations supports current momentum, confirming the projected P/S of Assertio Holdings, Inc. (ASRT). The brand's pricing power allows for the indexing of service costs, while the acquisition strategy refreshes the asset portfolio. The value of 1.50 reflects the baseline metric level, helping to assess the risk of a value trap and the resilience of revenue amid a market recession.
assertiotx.com (ASRT) - rincian metrik lan laporan keuangan
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- rincian valuasi buku bisnis:
- informasi babagan utang lan solvabilitas:
Utang marang Ekuitas Assertio Holdings, Inc.|ASRT - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Assertio|ASRT - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku ASRT|ASRT - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Assertio|Rasio cepet assertiotx.com
- rincian asil keuangan lan kelipatan valuasi:
ASRT - Bathi resik taunan|Bathi sing dikarepake Assertio Holdings, Inc.|ASRT - Periode bali modal bisnis|Prakiraan rega marang bathi Assertio|ASRT - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA ASRT|ASRT - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Assertio|ASRT - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan assertiotx.com|ASRT - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Assertio Holdings, Inc.
- statistik dodolan lan pendapatan perusahaan:
Pambiji fundamental perusahaan:Assertio Therapeutics ASRT
To isolate fundamental value from market noise, capital utilizes the ratio of current market capitalization to projected revenue, as reflected in the forward P/S indicator. The stable neurology drug portfolio of Assertio Holdings, Inc. (ASRT) reduces the volatility of this metric, allowing investors to use this chart to assess the fair price per unit of future sales and minimize the risk of overpaying during a shift in the market cycle.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Biogen BIIB|Neurocrine (NBIX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RGC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AXSM (Axsome Corp)|ACAD: Multiplikator Forward P/S|xenon-pharma.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Viking Therapeutics, Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Supernus Pharmaceuticals, Inc. SUPN|Rasio rega marang prakiraan pendapatan Catalyst Pharmaceuticals Inc (CPRX)|Rasio rega marang prakiraan pendapatan DNLI (Denali Corp)|Multiplikator Forward P/S HRMY (Harmony Biosciences)|BHVN: Kapitalisasi marang prakiraan pendapatan|Amylyx Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Trevi Therapeutics Inc TRVI|Praxis Medicines (PRAX) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan AVXL|CBLL (CeriBell, Inc.) - Multiplikator Forward P/S|PRTA - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Alector, Inc. (ALEC)|Rasio kapitalisasi marang dodolan sing dikarepake Annexon Biosciences|Omeros - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NGNE|AC Immune - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake voyagertherapeutics.com VYGR|Neumora Therapeutics, Inc. (NMRA) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan SCLX|TVGN (Tevogen Bio Holdings, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Alpha Cognition Corp (ACOG)|Multiplikator forward rega marang pendapatan CGTX (Cognition Therapeutics)|Rasio kapitalisasi marang dodolan sing dikarepake inhibikase.com|Multiplikator Forward P/S SAVA (Cassava Sciences)|Multiplikator Forward P/S Coya Therapeutics Inc COYA|VTGN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Ovid Therapeutics Inc. OVID|Acumen Pharmaceuticals (ABOS) - Rasio rega marang prakiraan pendapatan|cervomed.com - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan ATHE|CLNN (Clene Nanomedicine) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan PepGen Inc. (PEPG)|Jupiter Neurosciences, Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S RLMD (Relmada Therapeutics)|annovisbio.com (ANVS) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|GRCE: Multiplikator forward rega marang pendapatan|AIFF - Multiplikator Forward P/S|anewmeds.com (KLTO) - Rasio rega marang prakiraan pendapatan|NeuroSense Therapeutics Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep MetaVia, Inc. MTVA|Multiplikator Forward P/S NRXS|Multiplikator Forward P/S heliusmedical.com (HSDT)|Rasio rega marang prakiraan pendapatan Passage Bio PASG|Rasio kapitalisasi marang dodolan sing dikarepake Neuphoria Therapeutics, Inc. (NEUP)|NERV - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake athira.com ATHA|ADXN: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alzamend Neuro (ALZN)|Rasio rega marang prakiraan pendapatan Cyclerion Therapeutics Inc.|PTIX: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan KTTA (Pasithea Therapeutics)|Rasio rega marang pendapatan sing dikarepake CRGT|Multiplikator Forward P/S ATXI (Avenue Therapeutics, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Brainstorm Cell Therapeutics Inc. (BCLI)|CARA - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chromocell|ELYM (eliemtx.com) - Multiplikator forward rega marang pendapatan|Intra-Cellular Therapies, Inc. - Rega forward marang dodolan|LBPH (Longboard Pharmaceuticals, Inc.) - Multiplikator Forward P/S|MRNS: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan NKGen (NKGN)|NRBO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Sage Therapeutics, Inc. SAGE|synaptogen.com - Rasio rega marang prakiraan pendapatan|Trevena - Multiplikator Forward P/S|VIGL (Vigil Neuroscience) - Kapitalisasi marang prakiraan pendapatan|WENA: Multiplikator Forward P/S|CERE - Rasio kapitalisasi marang dodolan sing dikarepake
